Atrial Fibrillation Market – Global Industry Insights, Trends, Outlook,
and Opportunity Analysis, 2018–2026
Atrial fibrillation, also known as A-fib or AF, is an irregular heartbeat exemplified by rapid and
abnormal beating of the heart. Most episodes of atrial fibrillation have no symptoms or fewer
symptoms such as intermittent heart palpitations, lightheadedness, fainting, chest pain, and
shortness of breath. Atrial fibrillation is linked with an elevated risk of heart failure, stroke, and
dementia. The disease is a kind of supraventricular tachycardia. Risk factors associated with atrial
fibrillation include valvular heart disease such as coronary artery disease, heart failure, congenital
heart disease, and cardiomyopathy as well as high blood pressure. Valvular heart disease majorly
occurs due to rheumatic fever, while high alcohol intake, thyrotoxicosis, and diabetes mellitus are
other causes. The pulse and post-pulse measurement, via electrocardiogram (ECG) help in the
diagnosis of the disease.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/205
According to CDC, 2.7–6.1 million individuals in the U.S. alone suffer from atrial fibrillation and
this number is projected to increase with the growing aging population in this country. Around 2%
of the population below 65 years of age suffers from AF. However, around 9% of the population
aged 65 years and above suffers from AF. The global market for atrial fibrillation is expected to
witness significant growth, owing to rising prevalence of AF, primarily due to the rising number of
health cases such as diabetes, obesity, and hypertension. The geriatric population is more
susceptible to this condition due to their weak immune system. Rising adoption of catheter ablation
procedures is expected to fuel growth of the atrial fibrillation market over the forecast period
(2016–2024).
Atrial Fibrillation Market Taxonomy
On the basis of treatment type, the global market is segmented into:
•Non-pharmacological